Breaking News
9 hours ago
Simantini Singh Deo
Rinascera Therapeutics launches with initial funding to advance treatments for rare genetic skin diseases.
Simantini Singh Deo
Arcutis Biotherapeutics appoints Mirum Pharmaceuticals CEO Chris Peetz to its Board of Directors.
Simantini Singh Deo
Clearmind Medicine reports positive ex vivo results for its intranasal MEAI formulation in its Alcohol Use Disorder program.
Simantini Singh Deo
Novartis wins FDA traditional approval for Fabhalta to slow kidney function decline in IgA nephropathy patients.
Simantini Singh Deo